神药破灭了！

 

EPIC-SR trial: In fully vaccinated patients with risk factors for severe disease and patients (vaccinated or unvaccinated) without such risk factors, nirmatrelvir–ritonavir did not significantly shorten the time to alleviation of Covid-19 symptoms. *****wkheIsqMyu pic.twitter.com/NocUZxcxb6

— NEJM (@NEJM) April 3, 2024